Kronox Lab Sciences Limited is a specialized manufacturer of **High Purity Speciality Fine Chemicals** headquartered in Vadodara, Gujarat. The company serves as a critical supplier to high-growth, regulated industries including **pharmaceuticals (APIs and formulations)**, **nutraceuticals**, **biotech**, **solar energy**, and **scientific research**. Following its successful **Initial Public Offering (IPO)** in June 2024, the company has transitioned into a listed entity on the **NSE** and **BSE**, positioning itself for large-scale capacity expansion and product diversification. --- ### **Core Product Portfolio & Technical Standards** The company operates within a single reportable business segment, maintaining a diverse portfolio of over **185 products**. These chemicals are available in various physical forms, with particle sizes ranging from **10 mesh to 100 mesh**, and are manufactured to meet stringent international pharmacopeia standards. **Chemical Families & Derivatives:** * **Primary Groups:** Phosphates, Sulphates, Acetates, Chlorides, Citrates, Nitrates, Nitrites, Carbonates, EDTA derivatives, Succinates, and Gluconates. * **Customization:** Capability to manufacture according to bespoke customer specifications beyond standard offerings. **Quality Grades & Compliance:** The company’s products adhere to a wide array of global standards, ensuring suitability for sensitive applications: * **Pharmacopeia Grades:** IP, BP, EP, JP, USP. * **Food & Laboratory Grades:** FCC, LR, AR, GR, and ACS. * **Certifications:** **FSSC 22000 (Version 5)**, **FSSAI**, **KOSHER**, and **HALAL**. --- ### **Manufacturing Infrastructure & Strategic Location** Kronox operates a concentrated manufacturing hub in **Padra, Vadodara**, designed for logistical synergy and operational control. | Feature | Details | | :--- | :--- | | **Total Installed Capacity** | **7,242 MTPA** | | **Cumulative Area** | **1.88 Lakh Sq. ft** (approx. 17,454 sq. m.) | | **Current Facilities** | **Unit I, Unit II, and Unit III** (located within a 1 km radius) | | **Operational Standards** | **ISO 9001:2015**, **ISO 14001:2015**, **ISO 45001:2018**, **GMP**, and **GLP** | | **Logistical Advantage** | Proximity to **Kandla, Mundra, Hazira, and Nhava Sheva** ports | Each unit is equipped with integrated **storage and warehouse facilities** for finished goods and specialized areas for **bulk raw material stockpiling**. This infrastructure allows the company to mitigate supply chain volatility and protect **operating margins**. --- ### **Growth Catalyst: The Unit-IV Dahej Expansion** The primary lever for Kronox’s next phase of growth is the development of **Unit-IV** at the **GIDC, Dahej-II** industrial zone. This facility is strategically located within the **Delhi-Mumbai Industrial Corridor (DMIC)**. * **Land & Status:** The company has acquired **20,471 square meters** of land. **Consent to Establish (CTE)** has been received, and construction is commencing. * **Regulatory Timeline:** **Environmental Clearance (EC)** is anticipated by **September 2025**. Permissions for power, water, and waste management (CETP and BEIL) are already secured. * **Product Diversification:** Unit-IV will focus on high-margin specialty derivatives, including: * **Acetates, Adipates, and Ascorbates** * **Aspartates, Benzoates, and Glycinates** * **Lactates, Malates, Orotates, and Sorbates** * **Propionates and Succinates** --- ### **Financial Performance & Capital Structure** Kronox has demonstrated consistent profitability and maintains a robust, **debt-free** balance sheet. The company achieved a significant milestone by crossing the **₹100 Crore turnover** mark in FY2024-25. **Financial Summary (FY2023–FY2025):** | Particulars (₹ in Crores) | FY2024-25 | FY2023-24 | FY2022-23 | | :--- | :---: | :---: | :---: | | **Total Income** | **102.72** | **91.44** | **97.50** | | **Net Profit (PAT)** | **25.47** | **21.35** | **16.40** | | **PAT Growth (Y-o-Y)** | **19.23%** | **30.17%** | - | | **Operating Margin** | - | **31.51%** | - | | **Total Equity** | **90.11** | **66.31** | - | **Key Financial Metrics:** * **Liquidity:** Reported a **Current Ratio of 6.07** (FY24), with **Working Capital** rising to **₹38.93 crore**. * **Solvency:** The company maintains **Zero Net Debt** and a **Debt-Equity ratio of NA**. * **R&D Commitment:** Invested **₹45.64 Lakhs** in internal Research & Development during FY2024-25. * **Shareholder Returns:** The Board recommended a dividend of **5%** of face value (**₹0.50 per share**) for FY2023-24. --- ### **Global Reach & Market Dynamics** Kronox employs a business model focused on both **backward and forward integration** to ensure quality control and cost efficiency. * **Export Footprint:** The company exports to over **20 countries**, including the **USA, UK, Mexico, Australia, China, and UAE**. * **Foreign Exchange:** Export earnings grew from **₹2,168.01 Lakhs** in FY24 to **₹2,639.85 Lakhs** in FY25, while foreign exchange outgo remains minimal (**₹8.52 Lakhs**). * **Entry Barriers:** The business is protected by **high gestation periods** for facility setup, **technical expertise** required for high-purity synthesis, and **stringent regulatory documentation** (IP, BP, USP) which deter new entrants. --- ### **Risk Management & Compliance Framework** The company integrates risk mitigation into its strategic planning, focusing on financial stability and regulatory adherence. **Risk Mitigation Strategy:** * **Credit Risk:** Managed via the **Ind AS 109** expected credit loss model. As of July 2025, **no provisions** for credit losses were required. * **Liquidity & Market Risk:** Monitored through aging reports and financial ratios to ensure all liabilities (due within one year) are met. * **Foreign Exchange Risk:** Management actively monitors fluctuations to protect the fair value of future cash flows from export activities. **Regulatory Note:** In **July 2024**, the company received notices from the **NSE and BSE** regarding a procedural non-compliance with **Regulation 29** of SEBI (LODR) concerning prior intimation of a dividend recommendation. Management is tasked with resolving such penal actions to prevent potential restrictions on promoter shareholdings. The company remains a "going concern" with no material uncertainty regarding its ability to meet financial obligations.